US OptionsDetailed Quotes
LPTX241115P8000
- 0.00
- 0.000.00%
15min DelayClose Nov 6 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest8.00Strike Price0.00Turnover359.89%IV-115.63%PremiumNov 15, 2024Expiry Date4.29Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8621Delta0.1068Gamma0.84Leverage Ratio-0.0245Theta-0.0014Rho-0.73Eff Leverage0.0013Vega
Leap Therapeutics Stock Discussion
Leap Therapeutics announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12.66M shares of its common stock at a price of $2.82 per share and pre-funded warrants to purchase 1.52M shares of common stock at a price of $2.819 per share of common stock issuable upon exercise of the pre-funded warrants, in a private placement. Leap anticipates the gross proceeds from the private placement will be approxi...
NEWS
LEAP THERAPEUTICS ANNOUNCES $40 MILLION PRIVATE PLACEMENT
INTENDS TO USE NET PROCEEDS FROM FINANCING TO FUND CONTINUED DEVELOPMENT OF ITS LEAD MONOCLONAL ANTIBODY PROGRAM, DKN-01
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
Benzinga· 1 min ago
No comment yet